XOMA To Present New Data On PTH1R Program

- March 28th, 2017

XOMA (NASDAQ: XOMA) announced it will be showcasing preclinical data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting.

XOMA (NASDAQ: XOMA) announced it will be showcasing preclinical data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting.
As quoted in the press release:

The poster, which reports data from a pre-clinical study investigating the efficacy of the Company’s anti-PTH1R antagonist monoclonal antibody in reversing hypercalcemia, will be presented at the American Association for Cancer Research annual meeting, April 1-5, 2017, in Washington, DC.

Hypercalcemia is relatively common in patients with cancer, occurring in up to 30 percent of casesi. Hypercalcemia often occurs in patients with both solid tumors and hematologic malignancies due to release of a protein that activates the parathyroid hormone receptor (PTH1R) thereby leading to potentially dangerous calcium levels. Malignancy often is evident clinically by the time it causes hypercalcemia, and those patients often have a poor prognosis.
“Our PTH1R program began as an endocrine program, but because of its unique mechanism-of-action we believe it is also potentially beneficial to oncology patients suffering from hypercalcemia,” said Jim Neal, Chief Executive Officer of XOMA. “We seek partners who have a deep commitment to and expertise in drug development. We believe our PTH1R program could join the other antibodies in our extensive licensing portfolio of fully funded programs that are being advanced by partner companies to benefit patients suffering from a wide range of health conditions.”
Poster Presentation Details
Abstract Title: Impacting Humoral Hypercalcemia of Malignancy (HHM) and associated PTH1R-mediated morbidities: Characterization of an anti-PTH1R antagonist monoclonal antibody to reverse hypercalcemia

  • Session: Late-Breaking Research (LB-306): Experimental and Molecular Therapeutics 2
  • Date: Wednesday, April 5, 2017, 8:00am to 12:00pm ET
  • Location: Poster Section 34, Board 14

For additional information, please visit the AACR website: www.aacr.org.
About XOMA’s PTH1R Monoclonal Antibodies Program
XOMA has developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism. These antibodies have shown promising efficacy in in vivo studies and potentially could address high unmet medical needs, including primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).
HHM is present in many advanced cancers and is caused by high serum calcium due to increased levels of the PTH1R ligand PTH-related peptide (PTHrP).  Since current HHM treatments often fall short and many cancer patients die from ‘metabolic death’, PTH1R antibodies could prove beneficial for the treatment of HHM.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies.  Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics.  There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.

Click here to read the full press release.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *